Home
Conditions
Immunoproliferative Disorders

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,958 public trials 2,018 recruiting studies

Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate

NCT00298987

Conditions: Blast Crisis, Bone Marrow Diseases, Carcinogenesis, +22 more
Locations: Local Institution Corona, California, United States

Local Institution Aurora, Colorado, United States

Local Institution Colorado Springs, Colorado, United States

Local Institution Waterford, Connecticut, United States

View all 35 locations

View Trial Details

Completed

Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma

NCT00251394

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations: Massachusetts General Hospital Boston, Massachusetts, United States

Brigham and Women's Hospital Boston, Massachusetts, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Completed

Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's Lymphoma

NCT00147953

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations: University of Cologne Cologne, North Rhine-Westphalia, Germany

View Trial Details

Completed

Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant

NCT00063648

Conditions: Digestive System Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +5 more
Locations: Texas Children's Hospital Houston, Texas, United States

View Trial Details

Completed

A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Hodgkin Lymphoma (HL).

NCT00301314

Conditions: Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations: Royal Marsden NHS trust Sutton, Surrey, United Kingdom

View Trial Details

Completed

The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma

NCT00459069

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Beth Israel Deaconess Medical Center Boston, Massachusetts, United States

View Trial Details

Completed

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

NCT00230178

Conditions: Bone Marrow Diseases, Cancer, Hematologic Diseases, +14 more
Locations: Alta Bates Comprehensive Cancer Center Berkeley, California, United States

UCLA Medical Center Los Angeles, California, United States

Rocky Mountain Cancer Center Denver, Colorado, United States

University of Florida Health Science Center at Jacksonville Jacksonville, Florida, United States

View all 15 locations

View Trial Details

Completed

A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Non-Hodgkin Lymphoma (NHL).

NCT00301288

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations: Royal Marsden NHS trust Sutton, Surrey, United Kingdom

View Trial Details

Completed

A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

NCT00301301

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations: Royal Marsden NHS trust Sutton, Surrey, United Kingdom

View Trial Details

Completed

INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.

NCT00276003

Conditions: Cancer, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations: Lovelace Sandia Health Systems Dept of Hematology Albuquerque, New Mexico, United States

University of New Mexico Albuquerque, New Mexico, United States

View Trial Details

Immunoproliferative Disorders

Immunoproliferative Disorders trial results

Related conditions